We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report.
This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search.
| Behavioral Health Care | ||
| Acquirer | Target | Price |
| Center for Discovery | Cliffside Malibu | Merger |
| Biotechnology | ||
| Acquirer | Target | Price |
| Basilea Pharmaceutica International Limited | Exclusive license to derazantinib | $10 million |
| Proteintech Group | HumanZyme | N/A |
| Home Health Care & Hospice | ||
| Acquirer | Target | Price |
| AccentCare, Inc. | 2 home health agencies in Texas | N/A |
| Hospitals | ||
| Acquirer | Target | Price |
| Florida Hospital Ocala, Inc. | Munroe Regional Medical Center | N/A |
| Laboratories, MRI and Dialysis | ||
| Acquirer | Target | Price |
| Prenetics | DNAFit | N/A |
| Long-Term Care | ||
| Acquirer | Target | Price |
| 1031 exchange buyer | Riverwest Senior Living | $7.4 million |
| Sabra Health Care REIT | Arbor View & Legacy Assisted Living | $11.2 million |
| Mozart Healthcare | Nazareth Living Care Center | $6.3 million |
| Private healthcare investor | 4 skilled nursing facilities | N/A |
| Regional operator | 3 skilled nursing facilities | N/A |
| Real estate investor | Whitehouse Country Manor | N/A |
| Medical Devices | ||
| Acquirer | Target | Price |
| Boston Scientific Corporation | nVision Medical Corporation | $150 million |
| Pharmaceuticals | ||
| Acquirer | Target | Price |
| Procter & Gamble Co. | Merck’s consumer health business | $4.2 billion |
| Servier | Shire’s oncology business | $2.4 billion |
| Cardurion Pharmaceuticals | Exclusive license to CRD-733 | N/A |
| UCB S.A. | Rights to midazolam nasal spray | $150 million |
| Other | ||
| Acquirer | Target | Price |
| Artelo Biosciences, Inc. | Exclusive worldwide license to FABP inhibitor portfolio | N/A |
| BWX Technologies, Inc. | Nordion medical isotope business | N/A |
| Linical Co., Ltd | Accelovance, Inc. | N/A |
